{
  "eval_id": "S13",
  "timestamp": "2025-09-19T09:02:07.402360+00:00",
  "model": "gpt-4o",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "For a patient with HR+/HER2- breast cancer who has progressed after CDK4/6 inhibitors, it's important to consider subsequent treatment options that are supported by the label. Options might include further endocrine therapies or chemotherapy, depending on the patient's overall health, presence of visceral disease, and goals of therapy. Please refer to the specific SmPC or EPAR for detailed guidance, and feel free to email me the citation for further discussion."
}